The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Biomarin Pharmaceuticals

  • BMRN
  • NASDAQ
  • Consumer Products
  • Latest 61.37
  • Currency US$
  • Change 3.16
  • Percent Change 5.429 %
  • Volume 2,102,422
  • Wed Apr 16, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 58.74
  • Previous Close 58.21
  • High 61.45
  • Low 58.29
  • Bidx3 55.39
  • Askx3 61.89
  • 52-week High02/27 84.25
  • 52-week Low06/24 53.53
  • Beta 0.736
  • Market Cap 8,813.96M
  • EPS -1.29
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $548,480,000
  • Earnings $-176,350,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $568,780,000
  • Current Ratio 6.21

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,249,210,000
  • Liabilities $908,170,000
  • Liabilities-to-Equity Ratio 0.68

Price Ratios

  • Price to Sales 16.07
  • Price to Book 6.57
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Mar 3 $-0.34 Apr 24 $-0.49
Surprises Mar 3 -20.59% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 16, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Related Securities
Symbol Type Latest % Chg

Officers

  • Pierre LaPalme Chairman and Director
  • Jean-Jacques Bienaime Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

105 DIGITAL DRIVE
NOVATO, CA
94949

Phone: (415)-506-6700
Fax: (415)-3827889

ir@bmrn.com
www.bmrn.com

Ideas & Discussion

Live Discussion of BMRN on StockTwits